Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

As with climate change, why are we so slow to recognise the existential threat that drug use poses to humanity?

Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Gateshead Council is set to receive almost £2.5 million to support drug and alcohol treatment and recovery services.

People in Sedgwick County could see expanded treatment options for substance use as the city and county plan how they will ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held ...

Recognizing obesity as a chronic disease can improve treatment, address complications, and reshape healthcare strategies for ...

A health care researcher at Brown University has been named as a finalist to become dean of the University of Kansas’ School ...

9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center ...

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Orphan Drug and Rare Pediatric Disease designations follow U.S. FDA acceptance of IND application for ABO-101 for the treatment of PH1, with Phase 1/2 trial initiation anticipated in H1 2025.